The National Academies of Sciences, Engineering, and Medicine (NASEM) is pushing the US government – including the US Food and Drug Administration and National Institutes of Health – to do more to improve the representation of underrepresented populations in clinical trials.
National Academies Join Call For More Diversity In Trials
A new report from the National Academies of Sciences, Engineering, and Medicine issued a new report on the urgent need for better representation of underrepresented populations in clinical trials and research.
